USA flag logo/image

An Official Website of the United States Government

Transposon-mediated Gene Therapy for Fanconi Anemia

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70965
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
HL076908
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
DISCOVERY GENOMICS, INC.
614 MC KINLEY PL NE MINNEAPOLIS, MN -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Transposon-mediated Gene Therapy for Fanconi Anemia
Agency: HHS
Contract: 1R43HL076908-01
Award Amount: $235,588.00
 

Abstract:

DESCRIPTION (provided by applicant): Fanconi anemia (FA) is an inherited recessive disorder caused by deficiency of one of several (up to 9) proteins involved in the regulation of DNA repair. Patients exhibit birth defects, suffer from bone marrow failure early in life, and are prone to develop cancers including leukemia and solid tumors. The only effective treatment for FA is allogeneic bone marrow transplant, but many patients lack a matched donor. We propose the treatment of FA by introduction and expression the FANC gene by combining the cell-loading technology of MaxCyte, Inc., with the DNA integrating technology of Discovery Genomics, Inc. (DGI). In Specific Aim 1, we will first test the combination of these two technologies by using reporter genes to ascertain long-term gene transfer and expression in cultured hematopoietic cells. DGI will assemble transposons designed for introduction and expression of red fluorescent protein (dsRed). MaxCyte will then use its electroporation technology for high efficiency loading of the transposon DNA into several different hematopoietic cell lines (Jurkat, KB, K562) along with a source of transposase which mediates transposition from the newly-introduced plasmid DNA into chromosomal DNA. Gene expression will be assayed over time by flow cytometry, and molecular analyses (PCR, Southern blot) will be conducted for analysis of transposition into chromosomal targets. In Aim 2, DGI will assemble transposons designed for expression of the human FANC-C and FANC-A genes. MaxCyte will then load these transposons into lymphoblastoid cell lines established from patients with Fanconi anemia type C or A, respectively, testing these cell populations for reduced sensitivity to the DNA damaging agent mitomycin C as well as for transposition by molecular genetic analysis. These Phase 1 studies will provide the basis for further preclinical development of the combined cell loading and DNA integrating technologies targeting hematopoietic stem cells (HSC) in Phase 2. These studies will be ground-breaking in that long-term expression of genes after non-viral introduction into HSC has yet to be reported, and will require the efficient cell loading and integrating capacities provided by our combined technologies. Initial development cell loading / DNA integration approach is proposed here for Fanconi anemia, subsequently providing the technical basis for treatment of other inherited (immunodeficiencies, hemoglobinopathies) or acquired (AIDS) diseases.

Principal Investigator:

Perry B. Hackett
6126564485
PERRYH@DISCOVERYGENOMICS.NET

Business Contact:

John Haaland
6126564484
JOHNH@DISCOVERYGENOMICS.NET
Small Business Information at Submission:

DISCOVERY GENOMICS, INC.
DISCOVERY GENOMICS, INC. 614 MCKINLEY PL NE MINNEAPOLIS, MN 55413

EIN/Tax ID: 411990513
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No